Zhang Ying, Sun Xiaoying, Li Kexin, Wang Xiaomin, Cai Lijun, Li Xin, Zhou Min
Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai 201203, China.
Evid Based Complement Alternat Med. 2018 May 2;2018:8059256. doi: 10.1155/2018/8059256. eCollection 2018.
We evaluated the effectiveness of "the therapy of elimination first" in early acute mastitis, using four databases (CNKI, Wanfang, Embase, and PubMed). The study incorporated 2508 patients from 16 randomized controlled trials (RCTs). Included trials used Chinese oral medicine and applied the principle of "Eliminating Therapy" for the early treatment of acute mastitis, with simple antibiotic treatment as a control group. Meta-analysis showed significant differences between the overall effectiveness of oral Chinese medicine using Eliminating Therapy (OCM-ET) and western medicine using antibiotics (WM-A) (odds ratio [OR] = 4.43, 95% confidence interval [CI] = 3.21-6.12, = 9.04, and < 0.00001). Analysis of subgroups based on the use of classic or self-made preparations of the medicines showed smaller statistical heterogeneity among the different subgroups ( > 0.05, 2 ≤ 50%). The OCM-ET group showed significantly shorter pain relief times [mean difference (MD) = -3.08, 95% CI = (-5.90, -0.26), and = 0.03] and cure times [MD = -6.27, 95% CI = (-9.68, -2.85), and = 0.0003] than did the WM-A group. Our findings suggest that OCM-ET can shorten the duration of pain and improve cure time in early acute mastitis patients, with fewer adverse reactions. However, RCTs of higher quality with larger sample sizes are required to confirm these findings.
我们使用四个数据库(中国知网、万方、Embase和PubMed)评估了“先消法”治疗早期急性乳腺炎的有效性。该研究纳入了16项随机对照试验(RCT)中的2508例患者。纳入的试验使用中药口服制剂,并应用“消法”原则对急性乳腺炎进行早期治疗,以单纯抗生素治疗作为对照组。Meta分析显示,采用消法的中药口服制剂(OCM-ET)与使用抗生素的西药(WM-A)的总体有效性之间存在显著差异(优势比[OR]=4.43,95%置信区间[CI]=3.21-6.12, =9.04, <0.00001)。基于药物经典制剂或自制制剂使用情况的亚组分析显示,不同亚组之间的统计异质性较小( >0.05,2≤50%)。OCM-ET组的疼痛缓解时间[平均差(MD)=-3.08,95%CI=(-5.90,-0.26), =0.03]和治愈时间[MD=-6.27,95%CI=(-9.68,-2.85), =0.0003]均显著短于WM-A组。我们的研究结果表明,OCM-ET可以缩短早期急性乳腺炎患者的疼痛持续时间,提高治愈时间,且不良反应较少。然而,需要更高质量、更大样本量的RCT来证实这些发现。